About Advanced Targeting Systems
Founded in 1994, Advanced Targeting Systems (ATS) develops targeted cell elimination technologies for life science research. Its expertise centres on saporin-based conjugates that selectively deliver payloads to defined cell populations via receptor-mediated internalisation. The company’s molecular neurosurgery and targeted toxin technologies help researchers investigate cell function, create disease models and study neural circuitry with high specificity. ATS products support research in neuroscience, neurodegenerative disease, pain, pruritus, cancer biology, immunology and cell signalling.
The ATS portfolio includes targeted toxins, saporin reagents, monoclonal antibodies, secondary conjugates, ZAP internalisation screening systems and custom conjugation services. Its saporin platform enables the selective removal of cells expressing specific receptors, antigens or transporters in both in vitro and in vivo studies. Product families such as 192-IgG-SAP, CTB-SAP and other SAP conjugates are widely used in disease modelling, neuronal pathway research and target validation. The company also provides tools for antibody internalisation studies and the development of targeted research reagents.
Europa Biosite’s subsidiaries distribute for Advanced Targeting Systems in Ireland, Switzerland and the United Kingdom.